These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 18180487)

  • 21. Rx: higher prices.
    Kosterlitz J
    Natl J (Wash); 1993 Feb; 25(7):396-9. PubMed ID: 10125572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets.
    Outterson K
    Yale J Health Policy Law Ethics; 2005; 5(1):193-291. PubMed ID: 15742578
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
    Mendoza RL
    J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient and Plan Spending after State Specialty-Drug Out-of-Pocket Spending Caps.
    Yeung K; Barthold D; Dusetzina SB; Basu A
    N Engl J Med; 2020 Aug; 383(6):558-566. PubMed ID: 32757524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An Incomplete Prescription: President Trump's Plan to Address High Drug Prices.
    Sarpatwari A; Avorn J; Kesselheim AS
    JAMA; 2018 Jun; 319(23):2373-2374. PubMed ID: 29800027
    [No Abstract]   [Full Text] [Related]  

  • 26. Getting to the Root of High Prescription Drug Prices.
    Waxman H; Corr B; Martin K; Duong S
    Issue Brief (Commonw Fund); 2017 Jul; 2017():1-10. PubMed ID: 28700190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rx: Canadian drugs.
    Bugden S
    N Engl J Med; 2004 Mar; 350(11):1155. PubMed ID: 15014193
    [No Abstract]   [Full Text] [Related]  

  • 28. Compulsory licenses: a tool to improve global access to the HPV vaccine?
    Maybarduk P; Rimmington S
    Am J Law Med; 2009; 35(2-3):323-50. PubMed ID: 19697752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Should the United States government regulate prescription prices? A critical review.
    Patterson JA; Carroll NV
    Res Social Adm Pharm; 2020 May; 16(5):717-723. PubMed ID: 31248779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare.
    Critchley GJ; Zaric GS
    Health Econ; 2019 Aug; 28(8):1035-1051. PubMed ID: 31310424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmaceutical industry versus Medicaid--limits on state initiatives to control prescription-drug costs.
    Mello MM; Studdert DM; Brennan TA
    N Engl J Med; 2004 Feb; 350(6):608-13. PubMed ID: 14762190
    [No Abstract]   [Full Text] [Related]  

  • 32. German drug industry says pricing law is restricting access to some drugs.
    Stafford N
    BMJ; 2015 Nov; 351():h6205. PubMed ID: 26577819
    [No Abstract]   [Full Text] [Related]  

  • 33. The consumer welfare implications of governmental policies and firm strategy in markets for medicines.
    Chatterjee C; Kubo K; Pingali V
    J Health Econ; 2015 Dec; 44():255-73. PubMed ID: 26581076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prescription drug prices: why do some pay more than others do?
    Frank RG
    Health Aff (Millwood); 2001; 20(2):115-28. PubMed ID: 11260933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Several timely health law topics. Foreword.
    Coker KL; Singer L; Blum J
    Ann Health Law; 2010; 19(2):i-iii. PubMed ID: 21443145
    [No Abstract]   [Full Text] [Related]  

  • 37. Free statins disrupt pharmacy benefit plans.
    Reinke T
    Manag Care; 2012 Nov; 21(11):19-20. PubMed ID: 23236713
    [No Abstract]   [Full Text] [Related]  

  • 38. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
    Pavenik N
    Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Notice regarding HRSA grant requirement--participation in the 340B drug pricing program--HRSA. Notice.
    Fed Regist; 1998 Oct; 63(204):56656-8. PubMed ID: 10187117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Cost on Failure to Access Prescribed Pharmaceuticals: The Case of Statins.
    McRae I; van Gool K; Hall J; Yen L
    Appl Health Econ Health Policy; 2017 Oct; 15(5):625-634. PubMed ID: 28660496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.